Smoking Cessation Clinical Trial
Official title:
Interventions for Cardiovascular Disease: "Real-World" Effectiveness of Combined Pharmacotherapy and Behavioural Counseling for Smoking Cessation
Research Aims
The aims of this research study are:
1. To determine which of the following three smoking cessation medications is most
effective in achieving cessation:
- Nicotine Patch
- Nicotine Patch + gum or inhaler
- Varenicline (Champix;
2. To investigate how often participants experience neuropsychiatric symptoms over the
course of their cessation attempt and to assess whether:
- They occur more often when taking one medication versus another
- They occur more often in those with or without psychiatric illnesses.
Hypotheses to be Tested
The hypotheses to be tested include the following:
1. The CO-confirmed continuous abstinence rate from 5 weeks to 52 weeks following a target
quit date will be significantly higher in smokers receiving long-term transdermal NRT
in combination with other NRT products or those receiving varenicline compared to those
receiving transdermal NRT alone.
2. Some participants will experience neuropsychiatric symptoms during their cessation
attempt, and those in the varenicline group will experience a greater incidence of
neuropsychiatric symptoms than those in the groups receiving transdermal NRT alone or
in combination with other NRT products. Patients with psychiatric illnesses will report
higher levels of withdrawal symptoms than those without psychiatric illnesses.
Participants will be recruited from the UOHI Smoking Cessation Clinic and via media
advertisements. Following the baseline assessment, participants will be randomly assigned to
one of three groups:
1. 10-week standard regimen of transdermal NRT (NRT);
2. Long duration of transdermal NRT in combination with other NRT products (NRT+); or
3. Varenicline (VR).
Participants assigned to the "NRT" standard regimen group will follow a 10-week treatment of
nicotine patches alone.
Participants assigned to the "NRT+" long-duration group will follow the same regimen as the
NRT group, but will not be limited to a fixed declining dose strategy, nor limited to a
10-week duration (potential maximum dosage of 35mg/day and maximum treatment duration of up
to 22 weeks). Participants will also be provided with other NRT products (i.e., gum or
inhaler).
Participants assigned to the "VR" group will start the medication on the day of the baseline
assessment and set a target quit date any time within the 8 to 14 day period after baseline.
Participants will receive a 12-week supply of varenicline with a possible extension of up to
24 weeks.
All participants will receive six 15-minute counselling sessions from a nurse-counsellor
specializing in smoking cessation in accordance with nursing best-practice guidelines. These
sessions occur at 1, 3, 5, 8, and 10 weeks post target quit date. Counselling sessions will
focus on practical counselling (problem solving and skills training) and social support.
During the treatment phase, participants will complete questionnaires measuring withdrawal
and neuropsychiatric symptoms at 1, 3, 5, 8, and 10 weeks. These questionnaires will also be
completed at 22 and 52 weeks after the target quit date.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
Completed |
NCT04043728 -
Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study
|
N/A | |
Completed |
NCT04617444 -
The ESTxENDS Trial- Substudy on Effects of Using Electronic Nicotine Delivery Systems (ENDS) on Olfactory Function
|
N/A | |
Completed |
NCT02796391 -
Facilitating Smoking Cessation With Reduced Nicotine Cigarettes
|
Phase 2 | |
Completed |
NCT03397511 -
Incorporating Financial Incentives to Increase Smoking Cessation Among Asian Americans Residing in New York City
|
N/A | |
Not yet recruiting |
NCT05188287 -
A Culturally Tailored Smartphone Application for African American Smokers
|
N/A | |
Recruiting |
NCT05264428 -
The Effect of Honey on Lessening the Withdrawal Symptoms
|
N/A | |
Recruiting |
NCT05846841 -
Personalized Tobacco Treatment in Primary Care (MOTIVATE)
|
N/A | |
Completed |
NCT04133064 -
Assessment of the Pivot Breath Sensor: Single-Arm Cohort Study
|
N/A | |
Completed |
NCT03187730 -
Integrating Financial Management Counseling and Smoking Cessation Counseling to Reduce Health and Economic Disparities in Low-Income Immigrants
|
Phase 4 | |
Completed |
NCT03474783 -
To Explore the Factors Affecting the Effectiveness of Smoking Cessation
|
N/A | |
Completed |
NCT04635358 -
Feasibility Study of Smoking Cessation for the Staff of a Hospital Center
|
N/A | |
Terminated |
NCT03670264 -
BE Smokefree: Behavioral Economics Incentives to Engage Adolescents in Smoking Cessation
|
N/A | |
Not yet recruiting |
NCT06307496 -
VIDeOS for Smoking Cessation
|
N/A | |
Completed |
NCT02997657 -
Positive Psychotherapy for Smoking Cessation Enhanced With Text Messaging: A Randomized Controlled Trial
|
N/A | |
Completed |
NCT03206619 -
A Health Recommeder System to Tailor Message Preferences in a Smoking Cessation Programme
|
||
Completed |
NCT02905656 -
Strategies to Promote Cessation in Smokers Who Are Not Ready To Quit
|
N/A | |
Completed |
NCT02239770 -
Pharmacokinetics of Nicotine Film in Smokers
|
N/A | |
Completed |
NCT02562521 -
A Smoking Cessation Intervention for Yale Dining Employees
|
Phase 4 | |
Recruiting |
NCT02422914 -
Benefits of Tobacco Free Cigarette
|
N/A |